Evidence map›Paper›PMID 36155347›Full record

ArticleJMIR formative research2022

Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.

Tara Coffin, Deborah Bowen, Karen Lu, Elizabeth M Swisher, Nadine Rayes, Barbara Norquist, Stephanie V Blank, Douglas A Levine, Jamie Nadine Bakkum-Gamez, Gini F Fleming and 10 more

Registry-linked trialAbstract read
In one paragraph

Article in JMIR formative research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02993068 (Stand up to Cancer), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02993068 nasuspendednot on this map

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2017 to 2028Enrolled5,200ConditionsBARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene MutationArmsEducational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Whither social media and clinical genetics?American journal of medical genetics. Part A · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tara CoffinUniversity of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0003-1446-5792
Deborah BowenUniversity of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0002-5177-8520
Karen LuMD Anderson Cancer Center, Houston, TX, United States.ORCID https://orcid.org/0000-0002-5317-9927
Elizabeth M SwisherUniversity of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0003-2331-0434
Nadine RayesMD Anderson Cancer Center, Houston, TX, United States.ORCID https://orcid.org/0000-0002-8580-6075
Barbara NorquistUniversity of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0001-5992-7845
Stephanie V BlankMount Sinai Medical Center, New York, NY, United States.ORCID https://orcid.org/0000-0002-5333-9484
Douglas A LevineNew York University Langone Health, New York, NY, United States.ORCID https://orcid.org/0000-0003-1038-8232
Jamie Nadine Bakkum-GamezMayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0001-7018-8625
Gini F FlemingUniversity of Chicago, Chicago, IL, United States.ORCID https://orcid.org/0000-0003-2845-4023
Olufunmilayo I OlopadeUniversity of Chicago, Chicago, IL, United States.ORCID https://orcid.org/0000-0002-9936-1599
Iris RomeroUniversity of Chicago, Chicago, IL, United States.ORCID https://orcid.org/0000-0001-5849-5024
Alan D'AndreaDana-Farber Cancer Institute, Boston, MA, United States.ORCID https://orcid.org/0000-0001-6168-6294
Denise R NebgenMD Anderson Cancer Center, Houston, TX, United States.ORCID https://orcid.org/0000-0003-0576-3368
Christine PetersonMD Anderson Cancer Center, Houston, TX, United States.ORCID https://orcid.org/0000-0003-3316-0468
Mark F MunsellMD Anderson Cancer Center, Houston, TX, United States.ORCID https://orcid.org/0000-0001-9654-4958
Kathleen GavinMinnesota Ovarian Cancer Alliance, Minneapolis, MN, United States.ORCID https://orcid.org/0000-0001-8935-5358
Jamie CraseUniversity of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0003-0857-4650
Deborah PolinskySHARE, New York, NY, United States.ORCID https://orcid.org/0000-0002-7311-5752
Rebecca LechnerMinnesota Ovarian Cancer Alliance, Minneapolis, MN, United States.ORCID https://orcid.org/0000-0002-3809-6103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStrong participant recruitment practices are critical to public health research but are difficult to achieve. Traditional recruitment practices are often time consuming, costly, and fail to adequately target difficult-to-reach populations. Social media platforms such as Facebook are well-positioned to address this area of need, enabling researchers to leverage existing social networks and deliver targeted information. The MAGENTA (Making Genetic Testing Accessible) study aimed to improve the availability of genetic testing for hereditary cancer susceptibility in at-risk individuals through the use of a web-based communication system along with social media advertisements to improve reach.

objectiveThis paper is aimed to evaluate the effectiveness of Facebook as an outreach tool for targeting women aged ≥30 years for recruitment in the MAGENTA study.

methodsWe designed and implemented paid and unpaid social media posts with ongoing assessment as a primary means of research participant recruitment in collaboration with patient advocates. Facebook analytics were used to assess the effectiveness of paid and unpaid outreach efforts.

resultsOver the course of the reported recruitment period, Facebook materials had a reach of 407,769 people and 57,248 (14.04%) instances of engagement, indicating that approximately 14.04% of people who saw information about the study on Facebook engaged with the content. Paid advertisements had a total reach of 373,682. Among those reached, just <15% (54,117/373,682, 14.48%) engaged with the page content. Unpaid posts published on the MAGENTA Facebook page resulted in a total of 34,087 reach and 3131 instances of engagement, indicating that around 9.19% (3131/34,087) of people who saw unpaid posts engaged. Women aged ≥65 years reported the best response rate, with approximately 43.95% (15,124/34,410) of reaches translating to engagement. Among the participants who completed the eligibility questionnaire, 27.44% (3837/13,983) had heard about the study through social media or another webpage.

conclusionsFacebook is a useful way of enhancing clinical trial recruitment of women aged ≥30 years who have a potentially increased risk for ovarian cancer by promoting news stories over social media, collaborating with patient advocacy groups, and running paid and unpaid campaigns.

trial registrationClinicalTrials.gov NCT02993068; https://clinicaltrials.gov/ct2/show/NCT02993068.

Indexed as

Facebookgenetic testinghereditary cancermobile phoneonline social media recruitmentovarian cancersocial media

Identifiers

PMID36155347
PMCPMC9555323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.